Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.870
+0.090 (5.06%)
At close: Jun 20, 2025, 4:00 PM
1.875
+0.005 (0.27%)
After-hours: Jun 20, 2025, 7:58 PM EDT
Galmed Pharmaceuticals Employees
As of December 31, 2024, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,224,333
Market Cap
4.22M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GLMD News
- 25 days ago - Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - PRNewsWire
- 4 weeks ago - Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 6 weeks ago - Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PRNewsWire
- 7 weeks ago - Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PRNewsWire
- 2 months ago - Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PRNewsWire
- 2 months ago - Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - PRNewsWire
- 2 months ago - Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PRNewsWire
- 2 months ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - PRNewsWire